CAJ | 학술논문

目的：选择合适剂量的链脲佐菌素（STZ）诱导形成糖尿病鼠，而后用该鼠构建小鼠淋巴瘤的荷瘤模型。方法健康雄性Balb/c小鼠200只随机分为正常对照组（50只）和实验组（75、150、200 mg/kg d STZ，各50只）。一次性腹腔注射不同剂量STZ，定期监测小鼠体质量和血糖变化，观察各组造模成功率及死亡率，生存时间。糖尿病造模成功后皮下或尾静脉注射A20淋巴瘤细胞，分别在1个月后、3个月后观察成瘤率、死亡率，生存时间。结果 STZ 150 mg/kg组和STZ 200 mg/kg组与对照组相比，体重均显著降低，血糖显著升高(均P<0.05)，而STZ 75 mg/kg组改变不明显。STZ 200 mg/kg组死亡率明显高于STZ 150 mg/kg组，生存时间明显缩短（均P<0.05）。正常对照组、STZ 150 mg/kg组、STZ 200 mg/kg组皮下注射A20淋巴瘤细胞死亡率、成瘤率无统计学差异（P>0.05），尾静脉注射3个月后有统计学意义（P<0.05）。结论一次性腹腔注射STZ 150 mg/kg死亡率低，糖尿病成模率高，生存时间长，是构建Balb/c小鼠移植瘤模型的理想剂量。
목적：선택합괄제량적련뇨좌균소（STZ）유도형성당뇨병서，이후용해서구건소서림파류적하류모형。방법건강웅성Balb/c소서200지수궤분위정상대조조（50지）화실험조（75、150、200 mg/kg d STZ，각50지）。일차성복강주사불동제량STZ，정기감측소서체질량화혈당변화，관찰각조조모성공솔급사망솔，생존시간。당뇨병조모성공후피하혹미정맥주사A20림파류세포，분별재1개월후、3개월후관찰성류솔、사망솔，생존시간。결과 STZ 150 mg/kg조화STZ 200 mg/kg조여대조조상비，체중균현저강저，혈당현저승고(균P<0.05)，이STZ 75 mg/kg조개변불명현。STZ 200 mg/kg조사망솔명현고우STZ 150 mg/kg조，생존시간명현축단（균P<0.05）。정상대조조、STZ 150 mg/kg조、STZ 200 mg/kg조피하주사A20림파류세포사망솔、성류솔무통계학차이（P>0.05），미정맥주사3개월후유통계학의의（P<0.05）。결론일차성복강주사STZ 150 mg/kg사망솔저，당뇨병성모솔고，생존시간장，시구건Balb/c소서이식류모형적이상제량。
Objective To determine the optimal dosing of streptozotocin (STZ) for establishing lymphoma-bearing diabetic mouse models. Methods A total of 200 healthy male Balb/c mice were randomized into 4 groups (n=50) for intraperitoneal injection of a single dose of vehicle solution (control) or 75, 150, or 200 mg/kg STZ. The changes of body weight and blood glucose were observed regularly, and the success rate of modeling, mortality rate, and survival of the mice were recorded after the injections. The mice with successfully induced diabetes received subcutaneous or tail vein injection of A20 lymphoma cells, and the rate of tumorigenesis, mortality rate, and survival time were observed at 1 month and 3 months after tumor cell injection. Results Compared with the control group, the mice receiving STZ injection at 150 and 200 mg/kg showed significantly decreased body weight and increased blood glucose (P<0.05), while STZ at 75 mg/kg did not produced such obvious changes. STZ injection at 200 mg/kg resulted in a significantly higher mortality rate and shorter survival time than STZ at 150 mg/kg (P<0.05). In the control group and 150 and 200 mg/kg STZ groups, the rate of tumorigenesis or mortality rate showed no significant differences after subcutaneous injection of A20 lymphoma cells (P>0.05), but differed significantly at 3 months after tail vein injection of the tumor cells (P<0.05). Conclusion Intraperitoneal injection of STZ at 150 mg/kg is associated with a low mortality rate, a high successful modeling rate of diabetes and a long survival time in mice, and is therefore optimal for establishing diabetic mouse models bearing transplanted tumors.